

Fentanyl, Kratom and Xylazine: Perinatal Effect of New(er) and Emerging Substances of Concern

In the second webinar of a two-part series, **Marcela Smid, MD, MS, MA, Associate Professor at the University of Utah** and member of the **Society for Maternal-Fetal Medicine (SMFM)**, explores the growing impact of emerging substances—fentanyl, kratom, and xylazine—on pregnancy and maternal mental health.

These substances pose unique risks during the perinatal period, yet remain poorly understood in both research and clinical settings. Dr. Smid discusses what is currently known about their use, effects on pregnancy outcomes, and implications for newborn health. She also addresses the challenges of diagnosis and treatment in the context of substance use disorder and co-occurring mental health conditions.

This presentation provides evidence-informed insights for healthcare professionals, public health advocates, and anyone working to support pregnant women affected by substance use. Attendees will gain critical knowledge to better recognize, respond to, and care for those impacted by these evolving substance-related concerns.



Fentanyl, Kratom and Xylazine: Perinatal Effects of New(er) and Emerging Substances of Concern

Marcela Smid, MD, MS, MA

Associate Professor, University of Utah
Member, Society for Maternal-Fetal Medicine



WATCH NOW

Questions? Call 866.626.6847 | Text 855.999.3525 | Email or Chat at [MotherToBaby.org](https://www.MotherToBaby.org).

Disclaimer: MotherToBaby Fact Sheets are meant for general information purposes and should not replace the advice of your health care provider. MotherToBaby is a service of the non-profit Organization of Teratology Information Specialists (OTIS). Copyright by OTIS, June 20, 2024.